BTIG analyst Mark Massaro lowered the firm’s price target on Exagen (XGN) to $10 from $15 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XGN:
- Exagen price target lowered to $8 from $18 at B. Riley
- 3 ‘Strong Buy’ Stocks to Buy Now, 1/26/2026, According to Top Analysts
- Exagen: Temporary Headwinds, Strong AVISE Volume, and Undervalued Long‑Term Upside Support Buy Rating and $15 Target
- Exagen Announces Record 2025 Revenue and Strong Cash Position
- Exagen: Sustained Test Volume Growth and Solid Cash Runway Support Outperform Rating Despite Mixed Quarter